Patents Assigned to Seyltx, Inc.
  • Patent number: 12728121
    Abstract: The use of pharmaceutically active compounds for treating chronic lung diseases including idiopathic pulmonary fibrosis is disclosed. The compounds include NMDA receptor antagonists, glutamate 2b receptor antagonists and sigma receptor agonists. In particular, the use of bromantane, ifenprodil, radiprodil, bemithyl and repirinast are effective in treating idiopathic pulmonary fibrosis. Methods of use thereof are also disclosed.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: September 8, 2026
    Assignee: Seyltx, Inc.
    Inventor: Mark Williams
  • Patent number: 12478618
    Abstract: The use of glutamate 2b receptor antagonists and sigma receptor agonists as antitussives to treat or prevent a cough is disclosed. In preferred embodiments, the glutamate 2b receptor antagonist is ifenprodil or radiprodil. Preferred sigma receptor agonists include fluvoxamine, fluoxetine, excitalpram, and donepezil.
    Type: Grant
    Filed: August 21, 2024
    Date of Patent: November 25, 2025
    Assignee: Seyltx, Inc.
    Inventor: Mark Williams
  • Patent number: 12472170
    Abstract: The use of glutamate 2b receptor antagonists and sigma receptor agonists as antitussives to treat or prevent a cough is disclosed. In preferred embodiments, the glutamate 2b receptor antagonist is ifenprodil or radiprodil. Preferred sigma receptor agonists include fluvoxamine, fluoxetine, excitalpram, and donepezil.
    Type: Grant
    Filed: March 6, 2020
    Date of Patent: November 18, 2025
    Assignee: Seyltx, Inc.
    Inventor: Mark Williams